Evolution of the Pharmaceutical Industry through 2020 Training Course :

This highly focused 11/2 hour course provides a top-level overview of drug-product R&D strategies, merger alternatives, legislative and consumer impact, timelines and cycles that will affect capital costs and revenue streams, change in drug portfolios and the concomitant changes in patient acceptance. The course points out strategic pathways for managing in an evolutionary operating model.<br><br> <b>Module 1:</b><br> <li>Market expectations vs. performance from 1980-2000</li> <li>The why and how of product pipeline erosion</li> <li>Benchmarks for evaluating plant costs vs. yield</li> <li>The rise and solidification of generics</li> <li>Biologics: high risk, high reward, expensive capitalization</li> <li>Legislative, regulatory and healthcare management impacts</li><br><br> <b>Module 2:</b><br> <li>? Product portfolio evolution through 2020</li> <li>Infrastructure barriers to both change and entry</li> <li>The &ldquo;critical path&rdquo; avenue to patient tolerance</li> <li>Exogenous factors: counterfeiting, product identification</li> <li>Market sustainability as an aspect of patent life and the onset of competition</li> <li>Pathways to individual company growth</li></ul>